WO2002016408A3 - Analogues de gpe - Google Patents

Analogues de gpe Download PDF

Info

Publication number
WO2002016408A3
WO2002016408A3 PCT/US2001/041883 US0141883W WO0216408A3 WO 2002016408 A3 WO2002016408 A3 WO 2002016408A3 US 0141883 W US0141883 W US 0141883W WO 0216408 A3 WO0216408 A3 WO 0216408A3
Authority
WO
WIPO (PCT)
Prior art keywords
gpe
gly
pro
glu
analogs
Prior art date
Application number
PCT/US2001/041883
Other languages
English (en)
Other versions
WO2002016408A2 (fr
Inventor
Peter Gluckman
Tajrena Alexi
Original Assignee
Neuronz Ltd
Peter Gluckman
Tajrena Alexi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuronz Ltd, Peter Gluckman, Tajrena Alexi filed Critical Neuronz Ltd
Priority to AU2001289160A priority Critical patent/AU2001289160A1/en
Priority to EP01968959A priority patent/EP1351976A2/fr
Priority to US10/362,266 priority patent/US7112570B2/en
Publication of WO2002016408A2 publication Critical patent/WO2002016408A2/fr
Publication of WO2002016408A3 publication Critical patent/WO2002016408A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des analogues de GPE, en particulier, des analogues de GPE capables d'induire un effet physiologique équivalent à GPE chez un patient. Ces analogues de GPE consistent en des peptides dans lesquels le Gly de Gly-Pro-Glu est remplacé par Ala ou Ser ou Thr ou Pro, le Pro de Gly-Pro-Glu est remplacé par Ala ou Ser ou Thr ou Gly et le Glu de Gly-Pro-Glu étant remplacé par Asn ou Asp ou Gln. Ces analogues de GPE peuvent être utilisés dans tout procédé thérapeutique ou prophylactique impliquant GPE. Ces utilisations comprennent le traitement de lésions cérébrales aiguës et de maladies neurodégénératives, y compris, sans limitation, des lésions ou des maladies du système nerveux central. On administrera normalement ces analogues de GPE dans une composition ou une préparation pharmaceutique.
PCT/US2001/041883 2000-08-24 2001-08-24 Analogues de gpe WO2002016408A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001289160A AU2001289160A1 (en) 2000-08-24 2001-08-24 Gpe analogs
EP01968959A EP1351976A2 (fr) 2000-08-24 2001-08-24 Analogues de gpe
US10/362,266 US7112570B2 (en) 2000-08-24 2001-08-24 GPE analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ506534 2000-08-24
NZ50653400 2000-08-24

Publications (2)

Publication Number Publication Date
WO2002016408A2 WO2002016408A2 (fr) 2002-02-28
WO2002016408A3 true WO2002016408A3 (fr) 2003-04-24

Family

ID=19928066

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/041883 WO2002016408A2 (fr) 2000-08-24 2001-08-24 Analogues de gpe

Country Status (3)

Country Link
EP (1) EP1351976A2 (fr)
AU (1) AU2001289160A1 (fr)
WO (1) WO2002016408A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004536069A (ja) * 2001-05-24 2004-12-02 ニューロンズ・リミテッド Ｇｐｅ類縁体及びペプチドミメティック
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
FR2827170B1 (fr) * 2001-07-13 2004-07-16 Soc Extraction Principes Actif Utilisation de peptides pour augmenter l'adhesion cellulaire
US20100166859A1 (en) * 2006-01-16 2010-07-01 Luppo Edens Novel nutraceutical compositions and use thereof
AU2008262387A1 (en) 2007-06-08 2008-12-18 Massachusetts Institute Of Technology IGF for the treatment of Rett Syndrome and synaptic disorders
US9708366B2 (en) 2011-01-27 2017-07-18 Neuren Pharmaceuticals Ltd. Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate
SG187271A1 (en) * 2011-07-07 2013-02-28 Agency Science Tech & Res Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic
GB201613999D0 (en) 2016-08-16 2016-09-28 Neuro-Bio Ltd Neurodegenerative disorders
US20230312643A1 (en) * 2020-09-08 2023-10-05 Sunmarine Biotech Peptide derivative with collagenase inhibitory activity, and use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906614A (en) * 1985-01-23 1990-03-06 Gruenenthal Gmbh Method of treating posttraumatic nervous injuries with dipeptide derivatives
EP0366638A2 (fr) * 1988-10-27 1990-05-02 KabiGen AB Peptides neuromodulatoires
WO1993021216A1 (fr) * 1992-04-14 1993-10-28 Russian-American Institute For New Drug Development N-acylprolyldipeptides biologiquement actifs, presentant des effets antiamnesiques, antihypoxie et anorexigenes
FR2707170A1 (fr) * 1993-06-04 1995-01-13 Pasteur Institut Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26.
WO1995017204A1 (fr) * 1993-12-23 1995-06-29 Auckland Uniservices Limited Composition et procedes permettant d'ameliorer l'issue d'etats pathologiques du systeme nerveux
WO2000013650A2 (fr) * 1998-09-03 2000-03-16 Neuronz Limited Neuroprotection

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906614A (en) * 1985-01-23 1990-03-06 Gruenenthal Gmbh Method of treating posttraumatic nervous injuries with dipeptide derivatives
EP0366638A2 (fr) * 1988-10-27 1990-05-02 KabiGen AB Peptides neuromodulatoires
WO1993021216A1 (fr) * 1992-04-14 1993-10-28 Russian-American Institute For New Drug Development N-acylprolyldipeptides biologiquement actifs, presentant des effets antiamnesiques, antihypoxie et anorexigenes
FR2707170A1 (fr) * 1993-06-04 1995-01-13 Pasteur Institut Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26.
WO1995017204A1 (fr) * 1993-12-23 1995-06-29 Auckland Uniservices Limited Composition et procedes permettant d'ameliorer l'issue d'etats pathologiques du systeme nerveux
WO2000013650A2 (fr) * 1998-09-03 2000-03-16 Neuronz Limited Neuroprotection

Also Published As

Publication number Publication date
AU2001289160A1 (en) 2002-03-04
WO2002016408A2 (fr) 2002-02-28
EP1351976A2 (fr) 2003-10-15

Similar Documents

Publication Publication Date Title
BG66083B1 (bg) Фармацевтични състави, съдържащи антитела и антитела за профилактика и лечение на амилоидогенно заболяване
WO2001009118A3 (fr) Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
WO2004041067A3 (fr) Prevention et traitement d'une maladie synucleopathique
HUP0302114A2 (hu) Eritropoietin-fehérjét tartalmazó folyékony gyógyászati készítmény, eljárás előállítására és alkalmazása
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
HK1042655A1 (en) Use of erythropoietin in the production of the drugs for the treatment of cerebral ischaemia.
HUP0102365A2 (hu) Lipofil glükokortikoszteroidot és csak egy felületaktív anyagot tartalmazó micellákból álló gyógyszerkészítmények, valamint eljárás előállításukra
WO2002016408A3 (fr) Analogues de gpe
WO2001053457A3 (fr) Vaccins contre certains troubles neurodegeneratifs
GB2285219A (en) Use of norastemizole for the treatment of allergic disorders
WO2020219486A9 (fr) Compositions médicamenteuses à base de collagène peptidique et dispositifs et procédés pour les produire et les utiliser
WO2000072823A8 (fr) Preparations pour l'application d'agents anti-inflammatoires
WO2005123651A8 (fr) L-2-(a-hydroxypentyle)benzoates, leur elaboration et leur utilisation
WO2002046221A3 (fr) Proteines
WO2005046605A3 (fr) Compositions et procedes de traitement de maladies nerveuses
WO2002051379A3 (fr) Aerosol nasal thixotropique
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
JP4445263B2 (ja) 経皮薬物送達システム
MXPA02006511A (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido.
RU95110774A (ru) Олигонуклеотиды, терапевтические композиции, применение композиций
CN107184744A (zh) 番茄红素和葡萄籽提取物的组合物在制药中的用途
Gomes et al. Minerals in pharmacy and cosmetics
CN1048893C (zh) 一种治疗骨质增生药油及制作方法
BR9917605A (pt) Composição substituta de plasma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001968959

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10362266

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001968959

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP